Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.

Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.

The immunomodulatory effects of the CCR5-antagonist maraviroc might be beneficial in patients with a suboptimal immunological response, but results of different cART (combination antiretroviral therapy) intensification studies are conflicting. Therefore, we performed a 48-week placebo-controlled tri...

Full description

Bibliographic Details
Main Authors: Steven F L van Lelyveld, Julia Drylewicz, Maaike Krikke, Ellen M Veel, Sigrid A Otto, Clemens Richter, Robin Soetekouw, Jan M Prins, Kees Brinkman, Jan Willem Mulder, Frank Kroon, Ananja Middel, Jori Symons, Annemarie M J Wensing, Monique Nijhuis, José A M Borghans, Kiki Tesselaar, Andy I M Hoepelman, MIRS study group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4514679?pdf=render

Internet

http://europepmc.org/articles/PMC4514679?pdf=render

Similar Items